Insight Molecular Diagnostics Inc.
IMDX · In Vitro and in Vivo Diagnostic Substances
Latest available SEC filing: 10-Q ·
Latest disclosures
-
Latest financial period: Q2 2026
Financial facts · Filed
-
Form 10-Q
SEC filing · Filed
-
Silverman Lou: Form 4
Insider disclosure · Filed · Report period 01 Jul 2026
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
Company details and SEC sources
CIK 0001642380 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- IMDX on Nasdaq
- SEC industry group
- In Vitro and in Vivo Diagnostic Substances (Office of Life Sciences)
- Business address
- 2 International Plaza Dr., Suite 510, Nashville, TN, 37217
- Incorporated in
- CA
- Fiscal year end
- 31 December
- Former names on EDGAR
- OncoCyte Corp (to 17 Jun 2025), Oncocyte Corp (to 17 Jun 2025)
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields